MedTrace Logo

CardiaMend and Amiodarone for the Prevention of POAF

NCT05641883 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-12-08

No results posted yet for this study

Summary

The principal purpose of this investigator-initiated trial is to study the use of the CardiaMend device soaked in the anti-arrhythmic drug amiodarone, and how it may decrease the development of atrial fibrillation in patients that have undergone a coronary artery bypass surgery, or isolated valve surgery.

Conditions

Interventions

COMBINATION_PRODUCT

CardiaMend with antiarrhythmic

Pericardial patch with antiarrhythmic drug (amiodarone) topically applied

Sponsors & Collaborators

  • Saint Alphonsus Regional Medical Center

    lead OTHER

Principal Investigators

  • Robert Saeid Farivar, MD, PhD · Saint Alphonsus Regional Medical Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-05-31
Completion
2023-05-31
FDA Device
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05641883 on ClinicalTrials.gov